Yan Xiao

Array ( [id] => 19938903 [patent_doc_number] => 12311017 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-27 [patent_title] => Identification of immunologically protective neo-epitopes for the treatment of cancers [patent_app_type] => utility [patent_app_number] => 17/725932 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 10 [patent_no_of_words] => 11086 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403652 [patent_doc_number] => 20240287163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => ANTI-C1s ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/286471 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19968443 [patent_doc_number] => 12337026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Methods of treating inflammatory disorders with multivalent Fc compounds [patent_app_type] => utility [patent_app_number] => 17/718822 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 13 [patent_no_of_words] => 12646 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 148 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17718822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828338 [patent_doc_number] => 20220265642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/709324 [patent_app_country] => US [patent_app_date] => 2022-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18222054 [patent_doc_number] => 20230061048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => SELECTION OF PATIENTS FOR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 17/707081 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733377 [patent_doc_number] => 20220218836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => ENDOSIALIN-BINDING ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/707838 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10867 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707838 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157744 [patent_doc_number] => 20240150451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => ANTI-TAU ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/552504 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20291 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20882295 [patent_doc_number] => 12698326 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Anti-CD19 antibody formulations [patent_app_type] => utility [patent_app_number] => 17/700809 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7259 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17700809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19203974 [patent_doc_number] => 20240175873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS [patent_app_type] => utility [patent_app_number] => 18/282667 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17675 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19217890 [patent_doc_number] => 20240182594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-06 [patent_title] => USES OF ANTAGONIST, NON-DEPLETING OX40 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/551375 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18551375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479461 [patent_doc_number] => 20240327503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => SARS-COV-2 NEUTRALIZING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/550194 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157725 [patent_doc_number] => 20240150432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => FUSION PROTEIN OF TNFR2 AND APRIL BAFF RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/550055 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11352 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18550055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816789 [patent_doc_number] => 20250074996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => ANTI-GPRC5DxBCMAxCD3 TRISPECIFIC ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/546862 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 198 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020221 [patent_doc_number] => 20240076392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => ANTI-CD123 BINDING MOLECULES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/261145 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18261145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640650 [patent_doc_number] => 20220168388 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => METHODS AND COMPOSITIONS FOR TUSC2 IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/674800 [patent_app_country] => US [patent_app_date] => 2022-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17674800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464173 [patent_doc_number] => 20240317842 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS [patent_app_type] => utility [patent_app_number] => 18/263217 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30252 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -168 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923015 [patent_doc_number] => 20240026019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ANTI-TNFR2 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/263455 [patent_app_country] => US [patent_app_date] => 2022-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22674 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18263455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593436 [patent_doc_number] => 20220143009 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => COMBINATION OF ANTIBODY-DRUG CONJUGATE AND IMMUNE CHECKPOINT INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/586177 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067219 [patent_doc_number] => 20240101645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/273309 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53229 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18273309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109611 [patent_doc_number] => 20230002491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => HHLA2 AS A NOVEL INHIBITOR OF HUMAN IMMUNE SYSTEM AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/648792 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648792 [rel_patent_id] =>[rel_patent_doc_number] =>)